|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||73.69 / 89.09|
Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.
Today, Jim discusses Raytheon, tensions in Syria, bank earnings, Kohl's, Nordstrom and more!
The markets bounced back on easing trade tensions and the banks kicked off first-quarter earnings season.
The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.
Kohl's is a company with 100% of revenue coming from the United States.
Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.
For Women's History Month, Alpha Rising sat down with Nancy Lieberman, Of Counsel at Skadden, Arps. She was and still is the youngest person to ever make partner at her firm. She has worked on some of the biggest M&A deals in history -- and we should mention -- she's in a wheelchair and barely as use of her hands. Feel like a slacker yet? Good. Watch.
Traders should stay alert and nimble with LLY stock.
Former Executive Chairman Paul Jacobs is considering a leveraged buyout, which would be incredibly expensive and face tough regulatory scrutiny.
Jim Cramer focuses on Merck, Eli Lilly, Abbott Labs, Phillips 66, Five Below, and Cintas in the Lightning Round.
Do we trade on the news out of Washington? Jim Cramer talks about Larry Kudlow and his stand on economic growth.
The Indianapolis-based drugmaker launched Verzenio in October.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, APU, EBR, FNCB, TROW Downgrades: BSX, HLF, IROQ, KR, KWR, LABL, LLY, NX Initiations: AQN Read on to get TheStreet Quant Ratings' detailed report:
EMPERIAL clinical trials will evaluate the effect of Jardiance (empagliflozin) on exercise ability and heart failure symptoms in people with chronic heart failure
The price of LLY has climbed and the bearish price target on the Point and Figure chart is off the table.
Consider this LLY bullishly biased vertical call spread expiring in June.
Initiations/Exits, Price Target Updates and Ratings Changes are all here.
- Migraine Impact Report highlights physical, social and economic challenges of migraine -
- Reductions in the impact of genital psoriasis on sexual activity seen as early as one week -
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.